CD274 and non-small cell lung carcinoma: Additionally, pembrolizumab as a first‐line treatment provided longer OS than platinum‐based chemotherapy in NSCLC patients with a PD‐L1 tumor proportion score (TPS) ≥50% and those with PD‐L1 TPS ≥1%.5, 6